سوق أدوية الأنسولين البشري - النمو ، والاتجاهات ، وتأثير كوفيد -19 ، والتوقعات (2022 - 2027)

السوق مقسم حسب نوع المنتج (الأنسولين البشري التقليدي ، الأنسولين القاعدية أو طويل المفعول ، الأنسولين أو الأنسولين سريع المفعول ، تركيبات الأنسولين ، والأنسولين الحيوي) ، والجغرافيا.

لقطة السوق

Human Insulin Drugs Market Overview
Study Period: 2016-2027
Base Year: 2021
Fastest Growing Market: North America
Largest Market: North America
CAGR: 4.19 %
Human Insulin Drugs Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

نظرة عامة على السوق

من المتوقع أن يسجل سوق أدوية الأنسولين البشري معدل نمو سنوي مركب قدره 4.19٪ خلال الفترة المتوقعة من 2020-2025 ويقدر أن يصل إلى 29.9 مليار دولار أمريكي بحلول عام 2025. يعتبر مرض السكري عمومًا مرضًا مرتبطًا بنمط الحياة. بمرور الوقت ، ازدادت حالات الإصابة بالمرض بشكل شنيع ، مع زيادة عدد السكان في جميع أنحاء العالم. يحتاج ما يقرب من 100 مليون شخص حول العالم إلى الأنسولين ، بما في ذلك جميع الأشخاص الذين يعانون من مرض السكري من النوع الأول وما بين 10-25٪ من مرضى السكري من النوع 2. على الرغم من استخدام الأنسولين في علاج مرض السكري لأكثر من 90 عامًا ، إلا أن أكثر من نصف الأشخاص الذين يحتاجون إلى الأنسولين اليوم لا يزالون غير قادرين على تحمل تكاليفه والحصول عليه. يحتاج الأشخاص المصابون بداء السكري من النوع الأول إلى العلاج بالأنسولين ، والذي يركز على التحكم في مستويات السكر في الدم ، جنبًا إلى جنب مع الأنسولين والنظام الغذائي ونمط الحياة ، من أجل منع حدوث مضاعفات.

نطاق التقرير

تغطي الدراسة الجوانب التالية:

By Product Type
Basal or Long-acting Insulins (Value and Volume, 2012-2025)
Lantus (Insulin glargine)
Levemir (Insulin detemir)
Toujeo (Insulin glargine)
Tresiba (Insulin degludec)
Basaglar (Insulin glargine)
Bolus or Fast-acting Insulins (Value and Volume, 2012-2025)
NovoRapid/Novolog (Insulin aspart)
Humalog (Insulin lispro)
Apidra (Insulin glulisine)
FIASP (Insulin aspart)
Admelog (Insulin lispro)
Traditional Human Insulins (Value and Volume, 2012-2025)
Novolin/Actrapid/Insulatard
Humulin
Insuman
Combination Insulins (Value and Volume, 2012-2025)
NovoMix (Biphasic Insulin aspart)
Ryzodeg (Insulin degludec/Insulin aspart)
Xultophy (Insulin degludec/Liraglutide)
Soliqua/Suliqua (Insulin glargine/Lixisenatide)
Biosimilar Insulins (Value and Volume, 2012-2025)
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Geography
North America
United States (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Canada (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Rest of North America (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Europe
France (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Germany (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Italy (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Spain (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
United Kingdom (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Russia (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Rest of Europe (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Latin America
Mexico (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Brazil (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Rest of Latin America (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Asia-Pacific
Japan (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
South Korea (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
China (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
India (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Australia (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Vietnam (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Malaysia (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Indonesia (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Philippines (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Thailand (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Rest of Asia-Pacific (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Middle-East and Africa
Saudi Arabia (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Iran (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Egypt (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Oman (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
South Africa (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Rest of Middle-East and Africa (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins

Report scope can be customized per your requirements. Click here.

اتجاهات السوق الرئيسية

تزايد انتشار مرض السكري يقود السوق

ما يقرب من 100 مليون شخص حول العالم يحتاجون إلى الأنسولين ، بما في ذلك جميع الأشخاص الذين يعانون من مرض السكري من النوع الأول ، و 10-25 ٪ من مرضى السكري من النوع 2. على الرغم من استخدام الأنسولين في علاج مرض السكري في جميع أنحاء العالم لأكثر من 90 عامًا ، إلا أن أكثر من نصف السكان الذين يحتاجون إلى الأنسولين اليوم لا يزالون غير قادرين على تحمل تكاليفه أو الحصول عليه. يحتاج الأشخاص المصابون بداء السكري من النوع الأول إلى العلاج بالأنسولين ، ويركز العلاج على التحكم في مستويات السكر في الدم بالأنسولين والنظام الغذائي ونمط الحياة لمنع المضاعفات. يزداد البحث والتطوير في قطاعات الأنسولين عامًا بعد عام ، حيث يحاول الباحثون إخراج أفضل جزيء لاستخدام المرضى ، والحد من الآثار الجانبية القصوى ، وزيادة كفاءتها. وبالتالي ، من المرجح أن يؤدي الانتشار المتزايد للسمنة ومرض السكري في جميع أنحاء العالم إلى زيادة الطلب الكبير على الأنسولين ،

Human Insulin Drugs Market Key Trends

أمريكا الشمالية تهيمن على السوق

تهيمن أمريكا الشمالية على سوق الأنسولين البشري العالمي ، وخاصة الولايات المتحدة ، نظرًا لارتفاع معدل انتشار مرض السكري في المنطقة بسبب نمط الحياة المستقرة. يمثل عامل التكلفة مصدر القلق الرئيسي في الولايات المتحدة ، حيث يأتي ما يقرب من 50٪ من عائدات الأنسولين للشركات المصنعة من الدولة نفسها. تمثل الولايات المتحدة أعلى مبيعات من الأنسولين طويل المفعول ، النتوس ، في جميع أنحاء العالم. تعتبر غالبية شركات تصنيع أدوية مرضى السكر في البلاد سوقًا مهمًا لتحسين المبيعات العالمية الإجمالية. Lantus هو الأنسولين الأساسي الأكثر تدارًا في جميع أنحاء العالم ، ويمثل الحصة المهيمنة في سوق الولايات المتحدة. من المتوقع أن ينمو سوق أدوية الأنسولين البشري التقليدية في أمريكا الشمالية خلال فترة التوقعات ، نظرًا لقدرتها الاقتصادية على تحمل التكاليف من قبل المرضى. يمتلك Humulin أعلى حصة في السوق ، يليه Novolin. لا يوجد منافسون عامون لسوق عقاقير الأنسولين البشرية التقليدية في أمريكا الشمالية في الولايات المتحدة.

Human Insulin Drugs Market Growth by Region

مشهد تنافسي

يتم تعزيز سوق الأنسولين البشري العالمي بشكل كبير مع وجود ثلاث شركات تصنيع رئيسية لها وجود في السوق العالمية ، بينما يقتصر المصنعون الباقون على الشركات المصنعة المحلية أو الخاصة بالمنطقة. ساعدت عمليات الاندماج والاستحواذ التي حدثت بين اللاعبين في الماضي القريب الشركات على تعزيز وجودها في السوق. لدى Eli Lilly و Boehringer Ingelheim تحالفًا في تطوير وتسويق Basaglar (Insulin Glargine).

الأنسولين قيد التطوير:

تعمل شركة Novo Nordisk على تطوير أول أنسولين طويل المفعول مرة واحدة أسبوعياً (LAI287) وهو حالياً في المرحلة الثانية. ويشار إلى الأنسولين لمرضى السكري من النوع الأول والنوع الثاني. إيلي ليلي يطور أنسولين إف سي طويل المفعول (LY3209590) . "Basal insulin-Fc" هو جزيء كبير يتكون من أنسولين مصمم هندسيًا مدمجًا في مجال Fc مصمم لتوفير ملف تعريف قاعدي طويل المفعول. تتم دراسة LY3209590 لعلاج مرض السكري.

ستعمل أدوية الأنسولين عن طريق الفم على تعزيز السوق:

تعمل Biocon على تطوير Insulin Tregopil ، وهو قرص أنسولين يؤكل عن طريق الفم ، لعلاج داء السكري من النوع 1 والنوع 2. يمكن للأنسولين الفموي سريع المفعول أن يحسن التحكم في الجلوكوز بعد الأكل مع تقليل الآثار الجانبية وزيادة الالتزام ، وبالتالي يبشر بتحويل إدارة T1D. تعمل شركة Oramed Pharmaceuticals Inc. ، وهي شركة أدوية في المرحلة السريرية ، وتركز على تطوير أنظمة توصيل الأدوية عن طريق الفم ، على طرح أول منتج أنسولين عن طريق الفم في السوق ، وبالتالي توفير طريقة أكثر ملاءمة وفعالية وأمانًا تقديم العلاج بالأنسولين.

LIST OF TABLES AND FIGURES

 

LIST OF TABLES

1 Global Human Insulin Drugs Market: Revenue in USD million, by Product Type, 2012 - 2024
2 Global Human Insulin Drugs Market: Revenue in USD million, by Basal or Long-acting Insulins, 2012-2024
3 Global Human Insulin Drugs Market: Revenue in USD million, by Bolus or Fast-acting Insulins, 2012-2024
4 Global Human Insulin Drugs Market: Revenue in USD million, by Traditional Human Insulins, 2012-2024
5 Global Human Insulin Drugs Market: Revenue in USD million, by Combination Insulins, 2012-2024
6 Global Human Insulin Drugs Market: Revenue in USD million, by Biosimilar Insulins, 2012-2024
7 Global Human Insulin Drugs Market: Revenue in USD million, by Geography, 2012-2024
8 Global Human Insulin Drugs Market: Revenue in USD million, by North America, 2012-2024
9 Global Human Insulin Drugs Market: Revenue in USD million, by United States, by Segmentation, 2012-2024
10 Global Human Insulin Drugs Market: Revenue in USD million, by Canada, by Segmentation, 2012-2024
11 Global Human Insulin Drugs Market: Revenue in USD million, by Rest of North America, by Segmentation, 2012-2024
12 Global Human Insulin Drugs Market: Revenue in USD million, by Europe, 2012-2024
13 Global Human Insulin Drugs Market: Revenue in USD million, by United Kingdom, by Segmentation, 2012-2024
14 Global Human Insulin Drugs Market: Revenue in USD million, by Germany, by Segmentation, 2012-2024
15 Global Human Insulin Drugs Market: Revenue in USD million, by France, by Segmentation, 2012-2024
16 Global Human Insulin Drugs Market: Revenue in USD million, by Italy, by Segmentation, 2012-2024
17 Global Human Insulin Drugs Market: Revenue in USD million, by Spain, by Segmentation, 2012-2024
18 Global Human Insulin Drugs Market: Revenue in USD million, by Russia, by Segmentation, 2012-2024
19 Global Human Insulin Drugs Market: Revenue in USD million, by Rest of Europe, by Segmentation, 2012-2024
20 Global Human Insulin Drugs Market: Revenue in USD million, by Latin America, 2012-2024
21 Global Human Insulin Drugs Market: Revenue in USD million, by Mexico, by Segmentation, 2012-2024
22 Global Human Insulin Drugs Market: Revenue in USD million, by Brazil, by Segmentation, 2012-2024
23 Global Human Insulin Drugs Market: Revenue in USD million, by Rest of Latin America, by Segmentation, 2012-2024
24 Global Human Insulin Drugs Market: Revenue in USD million, by Asia-Pacific, 2012-2024
25 Global Human Insulin Drugs Market: Revenue in USD million, by Japan, by Segmentation, 2012-2024
26 Global Human Insulin Drugs Market: Revenue in USD million, by South Korea, by Segmentation, 2012-2024
27 Global Human Insulin Drugs Market: Revenue in USD million, by China, by Segmentation, 2012-2024
28 Global Human Insulin Drugs Market: Revenue in USD million, by India, by Segmentation, 2012-2024
29 Global Human Insulin Drugs Market: Revenue in USD million, by Australia, by Segmentation, 2012-2024
30 Global Human Insulin Drugs Market: Revenue in USD million, by Vietnam, by Segmentation, 2012-2024
31 Global Human Insulin Drugs Market: Revenue in USD million, by Malaysia, by Segmentation, 2012-2024
32 Global Human Insulin Drugs Market: Revenue in USD million, by Indonesia, by Segmentation, 2012-2024
33 Global Human Insulin Drugs Market: Revenue in USD million, by Philippines, by Segmentation, 2012-2024
34 Global Human Insulin Drugs Market: Revenue in USD million, by Thailand, by Segmentation, 2012-2024
35 Global Human Insulin Drugs Market: Revenue in USD million, by Rest of Asia-Pacific, by Segmentation, 2012-2024
36 Global Human Insulin Drugs Market: Revenue in USD million, by Middle East and Africa, 2012-2024
37 Global Human Insulin Drugs Market: Revenue in USD million, by Saudi Arabia, by Segmentation, 2012-2024
38 Global Human Insulin Drugs Market: Revenue in USD million, by Iran, by Segmentation, 2012-2024
39 Global Human Insulin Drugs Market: Revenue in USD million, by Egypt, by Segmentation, 2012-2024
40 Global Human Insulin Drugs Market: Revenue in USD million, by Oman, by Segmentation, 2012-2024
41 Global Human Insulin Drugs Market: Revenue in USD million, by South Africa, by Segmentation, 2012-2024
42 Global Human Insulin Drugs Market: Revenue in USD million, by Rest of Middle and Africa, by Segmentation, 2012-2024
43 Global Human Insulin Drugs Market: Revenue in USD million, by Market Indicators, 2012-2024

 

LIST OF FIGURES

1 Global Human Insulin Drugs Market, Revenue in USD million, 2012-2024
2 Global Countries Diabetes Population 2012-2024
3 Global Countries with High Obese Population, 2018
4 Global Human Insulin Drugs Market: Revenue in USD million, by Basal or Long-acting Insulins, 2012-2024
5 Global Human Insulin Drugs Market: Revenue in USD million, by Bolus or Fast-acting Insulins, 2012-2024
6 Global Human Insulin Drugs Market: Revenue in USD million, by Traditional Human Insulins, 2012-2024
7 Global Human Insulin Drugs Market: Revenue in USD million, by Combination Insulins, 2012-2024
8 Global Human Insulin Drugs Market: Revenue in USD million, by Biosimilar Insulins, 2012-2024
9 Global Human Insulin Drugs Market: Revenue in USD million, United States, 2012-2024
10 Global Human Insulin Drugs Market: Revenue in USD million, Canada, 2012-2024
11 Global Human Insulin Drugs Market: Revenue in USD million, Rest of North America, 2012-2024
12 Global Human Insulin Drugs Market: Revenue in USD million, United Kingdom, 2012-2024
13 Global Human Insulin Drugs Market: Revenue in USD million, Germany, 2012-2024
14 Global Human Insulin Drugs Market: Revenue in USD million, France, 2012-2024
15 Global Human Insulin Drugs Market: Revenue in USD million, Italy, 2012-2024
16 Global Human Insulin Drugs Market: Revenue in USD million, Spain, 2012-2024
17 Global Human Insulin Drugs Market: Revenue in USD million, Russia, 2012-2024
18 Global Human Insulin Drugs Market: Revenue in USD million, Rest of Europe, 2012-2024
19 Global Human Insulin Drugs Market: Revenue in USD million, Japan, 2012-2024
20 Global Human Insulin Drugs Market: Revenue in USD million, South Korea, 2012-2024
21 Global Human Insulin Drugs Market: Revenue in USD million, China, 2012-2024
22 Global Human Insulin Drugs Market: Revenue in USD million, India, 2012-2024
23 Global Human Insulin Drugs Market: Revenue in USD million, Australia, 2012-2024
24 Global Human Insulin Drugs Market: Revenue in USD million, Vietnam, 2012-2024
25 Global Human Insulin Drugs Market: Revenue in USD million, Malaysia, 2012-2024
26 Global Human Insulin Drugs Market: Revenue in USD million, Indonesia,  2012-2024
27 Global Human Insulin Drugs Market: Revenue in USD million, Philippines, 2012-2024
28 Global Human Insulin Drugs Market: Revenue in USD million, Thailand, 2012-2024
29 Global Human Insulin Drugs Market: Revenue in USD million, Rest of Asia-Pacific, 2012-2024
30 Global Human Insulin Drugs Market: Revenue in USD million, Saudi Arabia, 2012-2024
31 Global Human Insulin Drugs Market: Revenue in USD million, Iran, 2012-2024
32 Global Human Insulin Drugs Market: Revenue in USD million, Egypt, 2012-2024
33 Global Human Insulin Drugs Market: Revenue in USD million, Oman, 2012-2024
34 Global Human Insulin Drugs Market: Revenue in USD million, South Africa, 2012-2024
35 Global Human Insulin Drugs Market: Revenue in USD million, Rest of Middle and Africa, 2012-2024
36 Novo Nordisk AS Diabetes Care Revenue in USD million, 2016-2018
37 Novo Nordisk AS Diabetes Care Revenue Breakdown -  By Division (2018)
38 Novo Nordisk AS Diabetes Care Revenue Breakdown -  By Geographic Segment (2018)
39 Sanofi Aventis Revenue in USD million, 2016-2018
40 Sanofi Aventis Revenue Breakdown -  By Division (2018)
41 Sanofi Aventis Revenue Breakdown -  By Geographic Segment (2018)
42 Eli Lilly Revenue in USD million, 2016-2018
43 Eli Lilly Revenue Breakdown -  By Division (2018)
44 Eli Lilly Revenue Breakdown -  By Geographic Segment (2018)
45 Biocon Revenue in USD million, 2016-2018
46 Biocon Revenue Breakdown -  By Division (2018)
47 Biocon Revenue Breakdown -  By Geographic Segment (2018)
48 Pfizer Revenue in USD million, 2016-2018
49 Pfizer Revenue Breakdown -  By Division (2018)
50 Pfizer Revenue Breakdown -  By Geographic Segment (2018)
51 Julphar Revenue in USD million, 2016-2018
52 Julphar Revenue Breakdown -  By Division (2018)
53 Julphar Revenue Breakdown -  By Geographic Segment (2018)
54 Exir Revenue in USD million, 2016-2018
55 Exir Revenue Breakdown -  By Division (2018)
56 Exir Revenue Breakdown -  By Geographic Segment (2018)
57 Sedico Revenue in USD million, 2016-2018
58 Sedico Revenue Breakdown -  By Division (2018)
59 Sedico Revenue Breakdown -  By Geographic Segment (2018)
60 Wockhardt Revenue in USD million, 2016-2018
61 Wockhardt Revenue Breakdown -  By Division (2018)
62 Wockhardt Revenue Breakdown -  By Geographic Segment (2018)
63 Company Share Analysis (2018)

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Drivers

    3. 4.3 Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product Type

      1. 5.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2025)

        1. 5.1.1.1 Lantus (Insulin glargine)

        2. 5.1.1.2 Levemir (Insulin detemir)

        3. 5.1.1.3 Toujeo (Insulin glargine)

        4. 5.1.1.4 Tresiba (Insulin degludec)

        5. 5.1.1.5 Basaglar (Insulin glargine)

      2. 5.1.2 Bolus or Fast-acting Insulins (Value and Volume, 2012-2025)

        1. 5.1.2.1 NovoRapid/Novolog (Insulin aspart)

        2. 5.1.2.2 Humalog (Insulin lispro)

        3. 5.1.2.3 Apidra (Insulin glulisine)

        4. 5.1.2.4 FIASP (Insulin aspart)

        5. 5.1.2.5 Admelog (Insulin lispro)

      3. 5.1.3 Traditional Human Insulins (Value and Volume, 2012-2025)

        1. 5.1.3.1 Novolin/Actrapid/Insulatard

        2. 5.1.3.2 Humulin

        3. 5.1.3.3 Insuman

      4. 5.1.4 Combination Insulins (Value and Volume, 2012-2025)

        1. 5.1.4.1 NovoMix (Biphasic Insulin aspart)

        2. 5.1.4.2 Ryzodeg (Insulin degludec/Insulin aspart)

        3. 5.1.4.3 Xultophy (Insulin degludec/Liraglutide)

        4. 5.1.4.4 Soliqua/Suliqua (Insulin glargine/Lixisenatide)

      5. 5.1.5 Biosimilar Insulins (Value and Volume, 2012-2025)

        1. 5.1.5.1 Insulin Glargine Biosimilars

        2. 5.1.5.2 Human Insulin Biosimilars

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States (Value and Volume, 2012-2025)

          1. 5.2.1.1.1 Basal or Long-acting Insulins

          2. 5.2.1.1.2 Bolus or Fast-acting Insulins

          3. 5.2.1.1.3 Traditional Human Insulins

          4. 5.2.1.1.4 Combination Insulins

          5. 5.2.1.1.5 Biosimilar Insulins

        2. 5.2.1.2 Canada (Value and Volume, 2012-2025)

          1. 5.2.1.2.1 Basal or Long-acting Insulins

          2. 5.2.1.2.2 Bolus or Fast-acting Insulins

          3. 5.2.1.2.3 Traditional Human Insulins

          4. 5.2.1.2.4 Combination Insulins

          5. 5.2.1.2.5 Biosimilar Insulins

        3. 5.2.1.3 Rest of North America (Value and Volume, 2012-2025)

          1. 5.2.1.3.1 Basal or Long-acting Insulins

          2. 5.2.1.3.2 Bolus or Fast-acting Insulins

          3. 5.2.1.3.3 Traditional Human Insulins

          4. 5.2.1.3.4 Combination Insulins

          5. 5.2.1.3.5 Biosimilar Insulins

      2. 5.2.2 Europe

        1. 5.2.2.1 France (Value and Volume, 2012-2025)

          1. 5.2.2.1.1 Basal or Long-acting Insulins

          2. 5.2.2.1.2 Bolus or Fast-acting Insulins

          3. 5.2.2.1.3 Traditional Human Insulins

          4. 5.2.2.1.4 Combination Insulins

          5. 5.2.2.1.5 Biosimilar Insulins

        2. 5.2.2.2 Germany (Value and Volume, 2012-2025)

          1. 5.2.2.2.1 Basal or Long-acting Insulins

          2. 5.2.2.2.2 Bolus or Fast-acting Insulins

          3. 5.2.2.2.3 Traditional Human Insulins

          4. 5.2.2.2.4 Combination Insulins

          5. 5.2.2.2.5 Biosimilar Insulins

        3. 5.2.2.3 Italy (Value and Volume, 2012-2025)

          1. 5.2.2.3.1 Basal or Long-acting Insulins

          2. 5.2.2.3.2 Bolus or Fast-acting Insulins

          3. 5.2.2.3.3 Traditional Human Insulins

          4. 5.2.2.3.4 Combination Insulins

          5. 5.2.2.3.5 Biosimilar Insulins

        4. 5.2.2.4 Spain (Value and Volume, 2012-2025)

          1. 5.2.2.4.1 Basal or Long-acting Insulins

          2. 5.2.2.4.2 Bolus or Fast-acting Insulins

          3. 5.2.2.4.3 Traditional Human Insulins

          4. 5.2.2.4.4 Combination Insulins

          5. 5.2.2.4.5 Biosimilar Insulins

        5. 5.2.2.5 United Kingdom (Value and Volume, 2012-2025)

          1. 5.2.2.5.1 Basal or Long-acting Insulins

          2. 5.2.2.5.2 Bolus or Fast-acting Insulins

          3. 5.2.2.5.3 Traditional Human Insulins

          4. 5.2.2.5.4 Combination Insulins

          5. 5.2.2.5.5 Biosimilar Insulins

        6. 5.2.2.6 Russia (Value and Volume, 2012-2025)

          1. 5.2.2.6.1 Basal or Long-acting Insulins

          2. 5.2.2.6.2 Bolus or Fast-acting Insulins

          3. 5.2.2.6.3 Traditional Human Insulins

          4. 5.2.2.6.4 Combination Insulins

          5. 5.2.2.6.5 Biosimilar Insulins

        7. 5.2.2.7 Rest of Europe (Value and Volume, 2012-2025)

          1. 5.2.2.7.1 Basal or Long-acting Insulins

          2. 5.2.2.7.2 Bolus or Fast-acting Insulins

          3. 5.2.2.7.3 Traditional Human Insulins

          4. 5.2.2.7.4 Combination Insulins

          5. 5.2.2.7.5 Biosimilar Insulins

      3. 5.2.3 Latin America

        1. 5.2.3.1 Mexico (Value and Volume, 2012-2025)

          1. 5.2.3.1.1 Basal or Long-acting Insulins

          2. 5.2.3.1.2 Bolus or Fast-acting Insulins

          3. 5.2.3.1.3 Traditional Human Insulins

          4. 5.2.3.1.4 Combination Insulins

          5. 5.2.3.1.5 Biosimilar Insulins

        2. 5.2.3.2 Brazil (Value and Volume, 2012-2025)

          1. 5.2.3.2.1 Basal or Long-acting Insulins

          2. 5.2.3.2.2 Bolus or Fast-acting Insulins

          3. 5.2.3.2.3 Traditional Human Insulins

          4. 5.2.3.2.4 Combination Insulins

          5. 5.2.3.2.5 Biosimilar Insulins

        3. 5.2.3.3 Rest of Latin America (Value and Volume, 2012-2025)

          1. 5.2.3.3.1 Basal or Long-acting Insulins

          2. 5.2.3.3.2 Bolus or Fast-acting Insulins

          3. 5.2.3.3.3 Traditional Human Insulins

          4. 5.2.3.3.4 Combination Insulins

          5. 5.2.3.3.5 Biosimilar Insulins

      4. 5.2.4 Asia-Pacific

        1. 5.2.4.1 Japan (Value and Volume, 2012-2025)

          1. 5.2.4.1.1 Basal or Long-acting Insulins

          2. 5.2.4.1.2 Bolus or Fast-acting Insulins

          3. 5.2.4.1.3 Traditional Human Insulins

          4. 5.2.4.1.4 Combination Insulins

          5. 5.2.4.1.5 Biosimilar Insulins

        2. 5.2.4.2 South Korea (Value and Volume, 2012-2025)

          1. 5.2.4.2.1 Basal or Long-acting Insulins

          2. 5.2.4.2.2 Bolus or Fast-acting Insulins

          3. 5.2.4.2.3 Traditional Human Insulins

          4. 5.2.4.2.4 Combination Insulins

          5. 5.2.4.2.5 Biosimilar Insulins

        3. 5.2.4.3 China (Value and Volume, 2012-2025)

          1. 5.2.4.3.1 Basal or Long-acting Insulins

          2. 5.2.4.3.2 Bolus or Fast-acting Insulins

          3. 5.2.4.3.3 Traditional Human Insulins

          4. 5.2.4.3.4 Combination Insulins

          5. 5.2.4.3.5 Biosimilar Insulins

        4. 5.2.4.4 India (Value and Volume, 2012-2025)

          1. 5.2.4.4.1 Basal or Long-acting Insulins

          2. 5.2.4.4.2 Bolus or Fast-acting Insulins

          3. 5.2.4.4.3 Traditional Human Insulins

          4. 5.2.4.4.4 Combination Insulins

          5. 5.2.4.4.5 Biosimilar Insulins

        5. 5.2.4.5 Australia (Value and Volume, 2012-2025)

          1. 5.2.4.5.1 Basal or Long-acting Insulins

          2. 5.2.4.5.2 Bolus or Fast-acting Insulins

          3. 5.2.4.5.3 Traditional Human Insulins

          4. 5.2.4.5.4 Combination Insulins

          5. 5.2.4.5.5 Biosimilar Insulins

        6. 5.2.4.6 Vietnam (Value and Volume, 2012-2025)

          1. 5.2.4.6.1 Basal or Long-acting Insulins

          2. 5.2.4.6.2 Bolus or Fast-acting Insulins

          3. 5.2.4.6.3 Traditional Human Insulins

          4. 5.2.4.6.4 Combination Insulins

          5. 5.2.4.6.5 Biosimilar Insulins

        7. 5.2.4.7 Malaysia (Value and Volume, 2012-2025)

          1. 5.2.4.7.1 Basal or Long-acting Insulins

          2. 5.2.4.7.2 Bolus or Fast-acting Insulins

          3. 5.2.4.7.3 Traditional Human Insulins

          4. 5.2.4.7.4 Combination Insulins

          5. 5.2.4.7.5 Biosimilar Insulins

        8. 5.2.4.8 Indonesia (Value and Volume, 2012-2025)

          1. 5.2.4.8.1 Basal or Long-acting Insulins

          2. 5.2.4.8.2 Bolus or Fast-acting Insulins

          3. 5.2.4.8.3 Traditional Human Insulins

          4. 5.2.4.8.4 Combination Insulins

          5. 5.2.4.8.5 Biosimilar Insulins

        9. 5.2.4.9 Philippines (Value and Volume, 2012-2025)

          1. 5.2.4.9.1 Basal or Long-acting Insulins

          2. 5.2.4.9.2 Bolus or Fast-acting Insulins

          3. 5.2.4.9.3 Traditional Human Insulins

          4. 5.2.4.9.4 Combination Insulins

          5. 5.2.4.9.5 Biosimilar Insulins

        10. 5.2.4.10 Thailand (Value and Volume, 2012-2025)

          1. 5.2.4.10.1 Basal or Long-acting Insulins

          2. 5.2.4.10.2 Bolus or Fast-acting Insulins

          3. 5.2.4.10.3 Traditional Human Insulins

          4. 5.2.4.10.4 Combination Insulins

          5. 5.2.4.10.5 Biosimilar Insulins

        11. 5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2012-2025)

          1. 5.2.4.11.1 Basal or Long-acting Insulins

          2. 5.2.4.11.2 Bolus or Fast-acting Insulins

          3. 5.2.4.11.3 Traditional Human Insulins

          4. 5.2.4.11.4 Combination Insulins

          5. 5.2.4.11.5 Biosimilar Insulins

      5. 5.2.5 Middle-East and Africa

        1. 5.2.5.1 Saudi Arabia (Value and Volume, 2012-2025)

          1. 5.2.5.1.1 Basal or Long-acting Insulins

          2. 5.2.5.1.2 Bolus or Fast-acting Insulins

          3. 5.2.5.1.3 Traditional Human Insulins

          4. 5.2.5.1.4 Combination Insulins

          5. 5.2.5.1.5 Biosimilar Insulins

        2. 5.2.5.2 Iran (Value and Volume, 2012-2025)

          1. 5.2.5.2.1 Basal or Long-acting Insulins

          2. 5.2.5.2.2 Bolus or Fast-acting Insulins

          3. 5.2.5.2.3 Traditional Human Insulins

          4. 5.2.5.2.4 Combination Insulins

          5. 5.2.5.2.5 Biosimilar Insulins

        3. 5.2.5.3 Egypt (Value and Volume, 2012-2025)

          1. 5.2.5.3.1 Basal or Long-acting Insulins

          2. 5.2.5.3.2 Bolus or Fast-acting Insulins

          3. 5.2.5.3.3 Traditional Human Insulins

          4. 5.2.5.3.4 Combination Insulins

          5. 5.2.5.3.5 Biosimilar Insulins

        4. 5.2.5.4 Oman (Value and Volume, 2012-2025)

          1. 5.2.5.4.1 Basal or Long-acting Insulins

          2. 5.2.5.4.2 Bolus or Fast-acting Insulins

          3. 5.2.5.4.3 Traditional Human Insulins

          4. 5.2.5.4.4 Combination Insulins

          5. 5.2.5.4.5 Biosimilar Insulins

        5. 5.2.5.5 South Africa (Value and Volume, 2012-2025)

          1. 5.2.5.5.1 Basal or Long-acting Insulins

          2. 5.2.5.5.2 Bolus or Fast-acting Insulins

          3. 5.2.5.5.3 Traditional Human Insulins

          4. 5.2.5.5.4 Combination Insulins

          5. 5.2.5.5.5 Biosimilar Insulins

        6. 5.2.5.6 Rest of Middle-East and Africa (Value and Volume, 2012-2025)

          1. 5.2.5.6.1 Basal or Long-acting Insulins

          2. 5.2.5.6.2 Bolus or Fast-acting Insulins

          3. 5.2.5.6.3 Traditional Human Insulins

          4. 5.2.5.6.4 Combination Insulins

          5. 5.2.5.6.5 Biosimilar Insulins

  6. 6. MARKET INDICATORS

    1. 6.1 Type 1 Diabetes Population (2012-2025)

    2. 6.2 Type 2 Diabetes Population (2012-2025)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 COMPANY PROFILES

      1. 7.1.1 Novo Nordisk A/S

        1. 7.1.1.1 Overview

        2. 7.1.1.2 Products and Strategies

        3. 7.1.1.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.1.4 Ratio Analysis (5 Years)

        5. 7.1.1.5 Strength and Stability Analysis (5 Years)

        6. 7.1.1.6 Recent Developments

      2. 7.1.2 Sanofi S.A.

        1. 7.1.2.1 Overview

        2. 7.1.2.2 Products and Strategies

        3. 7.1.2.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.2.4 Ratio Analysis (5 Years)

        5. 7.1.2.5 Strength and Stability Analysis (5 Years)

        6. 7.1.2.6 Recent Developments

      3. 7.1.3 Eli Lilly and Company

        1. 7.1.3.1 Overview

        2. 7.1.3.2 Products and Strategies

        3. 7.1.3.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.3.4 Ratio Analysis (5 Years)

        5. 7.1.3.5 Strength and Stability Analysis (5 Years)

        6. 7.1.3.6 Recent Developments

      4. 7.1.4 Biocon Limited

        1. 7.1.4.1 Overview

        2. 7.1.4.2 Products and Strategies

        3. 7.1.4.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.4.4 Ratio Analysis (5 Years)

        5. 7.1.4.5 Strength and Stability Analysis (5 Years)

        6. 7.1.4.6 Recent Developments

      5. 7.1.5 Pfizer Inc.

        1. 7.1.5.1 Overview

        2. 7.1.5.2 Products and Strategies

        3. 7.1.5.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.5.4 Ratio Analysis (5 Years)

        5. 7.1.5.5 Strength and Stability Analysis (5 Years)

        6. 7.1.5.6 Recent Developments

      6. 7.1.6 Wockhardt

        1. 7.1.6.1 Overview

        2. 7.1.6.2 Products and Strategies

        3. 7.1.6.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.6.4 Ratio Analysis (5 Years)

        5. 7.1.6.5 Strength and Stability Analysis (5 Years)

        6. 7.1.6.6 Recent Developments

      7. 7.1.7 Julphar

        1. 7.1.7.1 Overview

        2. 7.1.7.2 Products and Strategies

        3. 7.1.7.3 Recent Developments

      8. 7.1.8 Exir

        1. 7.1.8.1 Overview

        2. 7.1.8.2 Products and Strategies

        3. 7.1.8.3 Recent Developments

      9. 7.1.9 Sedico

        1. 7.1.9.1 Overview

        2. 7.1.9.2 Products and Strategies

        3. 7.1.9.3 Recent Developments

    2. 7.2 COMPANY SHARE ANALYSIS

      1. 7.2.1 Novo Nordisk AS

      2. 7.2.2 Sanofi Aventis

      3. 7.2.3 Eli Lilly

      4. 7.2.4 Other Companies

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

Market size and volume of individual drugs provided for every country

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

تمت دراسة سوق أدوية الأنسولين البشري في الفترة من 2016 إلى 2027.

ينمو سوق أدوية الأنسولين البشرية بمعدل نمو سنوي مركب يبلغ 4.19٪ على مدى السنوات الخمس المقبلة.

تنمو أمريكا الشمالية بأعلى معدل نمو سنوي مركب خلال الفترة 2021-2026.

تمتلك أمريكا الشمالية أعلى حصة في عام 2021.

Novo Nordisk A / S و Eli Lilly and Company و Sanofi SA و Biocon Limited و Pfizer Inc. هي الشركات الكبرى العاملة في سوق أدوية الأنسولين البشرية.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!